ARTELO BIOSCIENCES, INC. 8-K

What Happened
ARTELO BIOSCIENCES, Inc. (ARTL) held its annual meeting of stockholders on July 17, 2026. Of 2,848,540 shares outstanding as of the May 22, 2026 record date, 1,172,203 shares (about 41.2%) were represented. Stockholders re-elected three Class III directors and approved an amendment to increase authorized common shares and a share-issuance approval related to an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5.

Key Details

• Meeting date: July 17, 2026; record date: May 22, 2026; shares outstanding: 2,848,540; shares represented: 1,172,203 (~41.2%).
• Director elections (votes For / Withhold / Broker non-votes): Gregory R. Reyes, M.D., Ph.D. — 179,416 / 55,405 / 937,382; Tamara A. Favorito — 176,821 / 58,000 / 937,382; Gregory D. Gorgas — 171,567 / 63,254 / 937,382.
• Amendment to Articles of Incorporation to increase authorized common shares from 166,666,667 to 500,000,000: For 985,717 / Against 164,845 / Abstain 21,641 (approved).
• Approval to issue more than 20% of issued and outstanding common stock under the Equity Purchase Agreement with Square Gate: For 91,158 / Against 65,155 / Abstain 78,508 / Broker non-votes 937,382 (approved).

Why It Matters
The approved increase in authorized shares gives the company legal capacity to issue many more shares (from ~166.7M to 500M), which can be used for future financings, equity compensation, or other corporate purposes. Shareholder approval to issue more than 20% of outstanding stock under the Square Gate Equity Purchase Agreement authorizes a potentially dilutive financing path that investors should monitor. Re-election of the three directors maintains board continuity.